Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed. Giving erlotinib after surgery may kill
any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well erlotinib works when given before and after
surgery in treating patients with muscle-invasive bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) OSI Pharmaceuticals